Exosomes in Liquid Biopsy: A Nanotool for Postradiotherapy Cancer Monitoring

Shi, Yixin; Qiu, Bingrun; Huang, Linyang; Li, Yiling; Ze, Yiting; Yang, Yue

doi:10.31083/j.fbl2707205

Cited by 4 publications

(5 citation statements)

References 170 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Zhu et al [ 73 ] used exosomes derived from adipose-derived stem cells to deliver microRNA-31 to promote cardiac angiogenesis in MI mice. Nowadays, exosomes have been applied in many fields, such as cancer monitoring after radiotherapy and the treatment of ventricular remodeling after MI, and exosomes for the treatment of cancer have also been approved for a number of clinical trials [ 74 , 75 , 76 ].…”

Section: Types and Properties Of Nanoparticlesmentioning

confidence: 99%

Advances in Nanoparticles in the Prevention and Treatment of Myocardial Infarction

Wei,

Xiao,

et al. 2024

Molecules

View full text Add to dashboard Cite

Myocardial infarction (MI) is one of the most prevalent types of cardiovascular disease. During MI, myocardial cells become ischemic and necrotic due to inadequate blood perfusion, leading to irreversible damage to the heart. Despite the development of therapeutic strategies for the prevention and treatment of MI, their effects are still unsatisfactory. Nanoparticles represent a new strategy for the pre-treatment and treatment of MI, and novel multifunctional nanoparticles with preventive and therapeutic capabilities hold promise for the prevention and treatment of this disease. This review summarizes the common types and properties of nanoparticles, and focuses on the research progress of nanoparticles for the prevention and treatment of MI.

show abstract

Section: Types and Properties Of Nanoparticlesmentioning

confidence: 99%

Advances in Nanoparticles in the Prevention and Treatment of Myocardial Infarction

Wei,

Xiao,

et al. 2024

Molecules

View full text Add to dashboard Cite

show abstract

“…Both ct-DNA and ct-RNA are released in body fluid by tumor tissue as a consequence of cell death, necrosis, or apoptosis, or encapsulated in vesicles as secretion products by living cells [15]. These encapsulated vesicles are distinguished by size in microvesicles, apoptotic bodies, circulating exosomes, and tumoreducated platelets (TEPs) and are actively released in body fluids containing different molecules, nucleic acid fragments, proteins such as chemokines, and cytokines [16]. Their analysis can provide information on the dynamic interplay between cancer and immune cells throughout the treatments [17].…”

Section: Biomarkersmentioning

confidence: 99%

“…Exosomes after radiotherapy suppress aggressive phenotypes of tumor cells, such as proliferation and migration. On the other hand, after irradiation, exosome-mediated signaling [16].…”

Section: Minimal Residual Disease Assessment In Radiotherapy By Circu...mentioning

confidence: 99%

“…On the other side, ct-RNA in the bloodstream might be linked to epigenetic pathways of tumor plasticity, development, and progression. Both ct-DNA and ct-RNA are released in body fluid by tumor tissue as a consequence of cell death, necrosis, or apoptosis, or Prediction of response Protect genomic from degradation -Technically challenge in isolation procedure -Million of Evs are released every day by many cell types Yixin Shi et al,2022[16] …”

mentioning

confidence: 99%

See 1 more Smart Citation

Liquid Biopsy-Guided Interventional Oncology: A Proof of Concept with a Special Focus on Radiotherapy and Radiology

Malara

Kovács

Bussu

et al. 2022

Cancers

View full text Add to dashboard Cite

Although the role of liquid biopsy (LB) to measure minimal residual disease (MRD) in the treatment of epithelial cancer is well known, the biology of the change in the availability of circulating biomarkers arising throughout treatments such as radiotherapy and interventional radio-oncology is less explained. Deep knowledge of how therapeutic effects can influence the biology of the release mechanism at the base of the biomarkers available in the bloodstream is needed for selecting the appropriate treatment-induced tumor circulating biomarker. Combining existing progress in the LB and interventional oncology (IO) fields, a proof of concept is provided, discussing the advantages of the traditional risk assessment of relapsing lesions, limitations, and the timing of detection of the circulating biomarker. The current review aims to help both interventional radiologists and interventional radiation oncologists evaluate the possibility of drawing a tailor-made board of blood-based surveillance markers to reveal subclinical diseases and avoid overtreatment.

show abstract

“…This makes them a focal point in research for potential use as organ-specific markers especially in liquid biopsies [ 5 ]. Due to their diverse molecular composition and the ability of their surface proteins to reflect their tissue of origin, exosomes represent a unique opportunity to identify those specific diseases [ 6 – 8 ]. In this light, it could be crucial to use those incredibly useful nanovescicles for early cancer diagnosis, especially for hardly detectable malignancies such as Laryngeal Cancer (LCa) [ 9 ].…”

Section: Introductionmentioning

confidence: 99%

Exosomes multiplex profiling, a promising strategy for early diagnosis of laryngeal cancer

Bocchetti,

Luce,

Iannarone

et al. 2024

J Transl Med

View full text Add to dashboard Cite

Background Exosomes are nanosized vesicles released from all cells into surrounding biofluids, including cancer cells, and represent a very promising direction in terms of minimally invasive approaches to early disease detection. They carry tumor-specific biological contents such as DNA, RNA, proteins, lipids, and sugars, as well as surface molecules that are able to pinpoint the cellular source. By the above criteria, exosomes may be stratified according to the presence of tissue and disease-specific signatures and, due to their stability in such biofluids as plasma and serum, they represent an indispensable source of vital clinical insights from liquid biopsies, even at the earliest stages of cancer. Therefore, our work aimed to isolate and characterize LCa patients’ derived exosomes from serum by Flow Cytometry in order to define a specific epitope signature exploitable for early diagnosis. Methods Circulating exosomes were collected from serum collected from 30 LCa patients and 20 healthy volunteers by the use of antibody affinity method exploiting CD63 specific surface marker. Membrane epitopes were then characterized by Flow cytometry multiplex analysis and compared between LCa Patients and Healthy donors. Clinical data were also matched to obtain statistical correlation. Results A distinct overexpression of CD1c, CD2, CD3, CD4, CD11c, CD14, CD20, CD44, CD56, CD105, CD146, and CD209 was identified in LCa patients compared to healthy controls, correlating positively with tumor presence. Conversely, CD24, CD31, and CD40, though not overexpressed in tumor samples, showed a significant correlation with nodal involvement in LCa patients (p < 0.01). Conclusion This approach could allow us to set up a cost-effective and less invasive liquid biopsy protocol from a simple blood collection in order to early diagnose LCa and improve patients’ outcomes and quality of life. Graphical Abstract

show abstract

Exosomes in Liquid Biopsy: A Nanotool for Postradiotherapy Cancer Monitoring

Cited by 4 publications

References 170 publications

Advances in Nanoparticles in the Prevention and Treatment of Myocardial Infarction

Advances in Nanoparticles in the Prevention and Treatment of Myocardial Infarction

Liquid Biopsy-Guided Interventional Oncology: A Proof of Concept with a Special Focus on Radiotherapy and Radiology

Exosomes multiplex profiling, a promising strategy for early diagnosis of laryngeal cancer

Contact Info

Product

Resources

About